Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug

Merck

On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab).

One opinion recommends approval of a new subcutaneous (SC) administration route and a solution for injection formulation. If approved, Keytruda SC could be administered in one minute every three weeks (395 mg) or two minutes every six weeks (790 mg).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.